VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
+4.9%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$31.7M
Cap. Flow
% of AUM
11.98%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| 1 |
DT Midstream
DTM
|
$1.86M |
| 2 |
ScottsMiracle-Gro
SMG
|
$878K |
| 3 |
Valero Energy
VLO
|
$790K |
| 4 |
FMC
FMC
|
$775K |
| 5 |
Delek US
DK
|
$761K |
Top Sells
| 1 |
COR
Coresite Realty Corporation
COR
|
$1.67M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
$551K |
| 4 |
Travere Therapeutics
TVTX
|
$479K |
| 5 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$448K |
Sector Composition
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Gladstone Capital
GLAD
$581M
| $440K | 0.17% |
18,968
-3,212
| -14% | -$74.5K |
|
127
Nuveen Floating Rate Income Fund
JFR
$1.13B
| $440K | 0.17% |
43,260
-7,170
| -14% | -$72.9K |
|
|
128
Travere Therapeutics
TVTX
$1.75B
| $438K | 0.17% |
14,116
-15,427
| -52% | -$479K |
|
|
GBT
129
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $437K | 0.17% |
14,938
+3,580
| +32% | +$105K |
|
|
DCF
130
DELISTED
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
DCF
| $433K | 0.16% |
46,633
-3,087
| -6% | -$28.7K |
|
131
Halozyme
HALO
$8.75B
| $432K | 0.16% |
10,738
+187
| +2% | +$7.52K |
|
132
Sixth Street Specialty
TSLX
$2.32B
| $431K | 0.16% |
18,424
-14,399
| -44% | -$337K |
|
133
BlackRock Limited Duration Income Trust
BLW
$548M
| $430K | 0.16% |
25,516
-1,604
| -6% | -$27K |
|
134
BlackRock Floating Rate Income Strategies Fund
FRA
$470M
| $424K | 0.16% |
31,606
-3,503
| -10% | -$47K |
|
135
Saratoga Investment
SAR
$401M
| $416K | 0.16% |
14,147
-2,436
| -15% | -$71.6K |
|
136
United Therapeutics
UTHR
$17.7B
| $414K | 0.16% |
1,918
-630
| -25% | -$136K |
|
137
Apellis Pharmaceuticals
APLS
$3.51B
| $413K | 0.16% |
8,725
+1,673
| +24% | +$79.2K |
|
138
Amicus Therapeutics
FOLD
$2.42B
| $413K | 0.16% |
35,800
-6,869
| -16% | -$79.2K |
|
139
Harmony Biosciences
HRMY
$2.16B
| $413K | 0.16% |
9,686
-4,605
| -32% | -$196K |
|
|
SAGE
140
DELISTED
Sage Therapeutics
SAGE
| $408K | 0.15% |
9,594
+3,314
| +53% | +$141K |
|
|
CCXI
141
DELISTED
ChemoCentryx, Inc.
CCXI
| $408K | 0.15% |
11,214
-4,928
| -31% | -$179K |
|
142
BlackRock Floating Rate Income Trust
BGT
$319M
| $406K | 0.15% |
29,022
-6,455
| -18% | -$90.3K |
|
|
BLUE
143
DELISTED
bluebird bio
BLUE
| $406K | 0.15% |
2,030
+977
| +93% | +$195K |
|
|
BPMC
144
DELISTED
Blueprint Medicines
BPMC
| $403K | 0.15% |
3,762
-1,540
| -29% | -$165K |
|
|
PHD
145
Pioneer Floating Rate Fund
PHD
$123M
| $403K | 0.15% |
34,718
-6,725
| -16% | -$78.1K |
|
146
Theravance Biopharma
TBPH
$692M
| $402K | 0.15% |
36,359
+11,957
| +49% | +$132K |
|
147
Ligand Pharmaceuticals
LGND
$3.25B
| $401K | 0.15% |
4,165
-1,789
| -30% | -$172K |
|
148
Enanta Pharmaceuticals
ENTA
$189M
| $400K | 0.15% |
5,353
-4,246
| -44% | -$317K |
|
149
Exelixis
EXEL
$9.95B
| $400K | 0.15% |
21,880
+1,783
| +9% | +$32.6K |
|
150
PTC Therapeutics
PTCT
$4.41B
| $400K | 0.15% |
10,034
-382
| -4% | -$15.2K |
|